1.85
+2.78%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jyong Biotech
Its shares trade under the ticker MENS. It has been listed since 17 June 2025.
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jun 2025
- Employees
- 29
- Website
- jyongbio.com ↗
- Head office
- 23F-3, NO.95, SEC. 1, XINTAI 5TH RD., NEW TAIPEI CITY
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Ms. Fu-Feng KuoChairwoman of the Board and Chief Executive Officer, since 2018
- Mr. Alfred YingChief Financial Officer
- Dr. Fenglin HsuDirector and Chief Technology Officer, since 2025
- Dr. Wanwen SuChief Scientific Officer
- Mr. Pang-Chief ChiIndependent Director
- Mr. Hung-Shu FanIndependent Director
- Mr. Ming Tsan HsuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates as a holding company developing biotechnology products
- Headquartered in Taipei with 29 full-time employees
- Focuses on plant-derived drugs for urinary system diseases
Weaknesses
- IPO scheduled for 2025-06-17, indicating limited market presence
- Relies on a small team of 29 employees for development and commercialization
- Dependent on botanical drug candidates at various stages of development
Opportunities
- Potential market expansion in the U.S., EU, and Asia for urinary system treatments
- Growth opportunities in botanical drug development for prostate-related conditions
- Commercialization of MCS-2 and PCP drug candidates in clinical stages
Threats
- Uncertainty around IPO date and market readiness for new drugs
- Competition in the biotechnology sector for botanical drug development
- Regulatory challenges for botanical drug approvals in target markets
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.